Ferring’s new labour induction therapy accepted for EU review

Ferring's new controlled-release removable misoprostol vaginal delivery system (MVDS) for the induction of labour has been accepted for European regulatory review.

The company's marketing authorisation application for the therapy – which is designed for the induction of labour among women with an unfavourable cervix – is now set to be reviewed through the European decentralised procedure.

Clinical studies involving more than 3,000 pregnant women showed that MVDS was able to decrease the time to vaginal delivery among patients compared to an alternative therapy option.

Labour induction is an increasingly common clinical indication for patients whose cervixes have not yet softened and thinned so that dilation can take place.

Pascal Danglas, executive vice-president for clinical and product development at Ferring Pharmaceuticals, said: "Ferring is committed to developing new and improved treatments in the area of reproductive health. We look forward to cooperating with the review process."

This comes after the new therapy was also accepted for US regulatory assessment last month.